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ARTICLE
Loss of microRNA-128 promotes cardiomyocyte
proliferation and heart regeneration
Wei Huang1,2, Yuliang Feng1, Jialiang Liang2, Hao Yu2, Cheng Wang3, Boyu Wang4, Mingyang Wang5, Lin Jiang2,
Wei Meng6, Wenfeng Cai2, Mario Medvedovic7, Jenny Chen7, Christian Paul2, W. Sean Davidson2,
Sakthivel Sadayappan 8, Peter J. Stambrook9, Xi-Yong Yu 1 & Yigang Wang2
The goal of replenishing the cardiomyocyte (CM) population using regenerative therapies
following myocardial infarction (MI) is hampered by the limited regeneration capacity of
adult CMs, partially due to their withdrawal from the cell cycle. Here, we show that
microRNA-128 (miR-128) is upregulated in CMs during the postnatal switch from proliferation
to terminal differentiation. In neonatal mice, cardiac-speciﬁc overexpression of miR-128
impairs CM proliferation and cardiac function, while miR-128 deletion extends proliferation of
postnatal CMs by enhancing expression of the chromatin modiﬁer SUZ12, which suppresses
p27 (cyclin-dependent kinase inhibitor) expression and activates the positive cell cycle
regulators Cyclin E and CDK2. Furthermore, deletion of miR-128 promotes cell cycle re-entry
of adult CMs, thereby reducing the levels of ﬁbrosis, and attenuating cardiac dysfunction
in response to MI. These results suggest that miR-128 serves as a critical regulator of
endogenous CM proliferation, and might be a novel therapeutic target for heart repair.
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The adult human heart fails to replenish the massive loss ofcardiomyocytes (CMs) caused by ischemia, which is theleading cause of death worldwide1. Intensive research has
recently focused on the development of regenerative therapies for
ischemic heart disease. Current regenerative approaches are
designed to repopulate lost CMs through transplantation of
exogenous stem cells from various sources with committed car-
diogenic potential2–4. The inability to differentiate efﬁciently,
poor cell survival, immaturity of differentiated CM, and
arrhythmia have all hampered the application of stem cell-based
therapy in clinical settings5. Alternatively, cell-free approaches
(such as stimulation of endogenous CM proliferation) have
emerged as an attractive option for promoting myocardial
regeneration.
There has been a longstanding dogma that adult mammalian
CMs are incapable of cell division. Recent studies, however, have
shown that 1-day-old neonatal mouse can regenerate its heart
through dedifferentiation and proliferation of pre-existing
CMs6,7, a phenomenon that is observed in lower vertebrates
such as adult zebraﬁsh and amphibians8. Unlike the adult zeb-
raﬁsh, the capacity of the neonatal mouse heart to regenerate is
diminished as early as 1 week after birth and remains limited
throughout adulthood. Various hypotheses have been proposed
to explain the varying capacities of different species to undergo
cardiac regeneration. Recent compelling evidence showing that
CMs have the potential to divide implies there is a latent regen-
erative potential when endogenous CMs are triggered to pro-
liferate. The most exciting one is the ﬁnding of limited self-
renewal of human adult CMs using measurements of carbon-14
(14C) content by accelerator mass spectrometry9–11. The reacti-
vation of CM proliferation, therefore, becomes even more
appealing for the potential of heart regeneration. Whether, how
and to what extent the endogenous proliferative ability of CMs is
sufﬁcient to restore adult heart function, however, remains largely
unknown.
MicroRNAs (miRNAs) constitute a class of small noncoding
RNAs that bind to the 3′ (untranslated region) UTR of target
mRNAs, resulting in the reduction of protein expression pre-
dominantly by destabilizing the target mRNAs and/or by inhi-
biting translation12,13. The miRNAs play pivotal roles in many
biological processes including apoptosis of CMs during MI14.
However, the miRNAs that regulate CM proliferation during
homeostasis and injury are not fully deﬁned.
In this study, we ﬁrst show that the expression of cardiac miR-
128 is lower in neonates than in adults, and is reduced during
neonatal heart regeneration. Furthermore, cardiac-speciﬁc over-
expression of miR-128 in early postnatal mice suppresses CM
proliferation and causes impaired cardiac function. Conversely,
knockout of miR-128 reactivates CM proliferation and cardiac
regeneration in the adult mice, in part through modulation of cell
cycle-related genes by targeting Suz12 in the heart. Collectively,
our results suggest that miR-128 functions as a critical regulator
of endogenous cardiac proliferation and regeneration.
Results
MiR-128 increases during postnatal heart growth. RNA
sequencing (RNA-seq) in mouse cardiac ventricles was performed
on postnatal days 1, 7, and 28 (P1, P7, and P28) to identify
potential miRNAs involved in the regulation of postnatal heart
growth. MiR-128 was robustly upregulated in P7 hearts as com-
pared to P1, which was further conﬁrmed by quantitative PCR
(qPCR) array (Supplementary Fig. 1A). As previously reported15,
miR-128 was predominantly expressed in brain tissue but was
also expressed in the heart (Supplementary Fig. 1B). Its expres-
sion in adult myocardium was further conﬁrmed by in situ
hybridization (ISH) (Supplementary Fig. 1C). To investigate the
role of miR-128 in cell cycle withdrawal during heart growth,
mouse hearts were harvested and sectioned at P1, P7, and P28
(Fig. 1a). As neonates (P1) progress to adulthood (P28), CMs
underwent a maturation process characterized by suppression of
cell proliferation as evidenced by decreased numbers of Ki67+
CMs (Fig. 1a, b). In addition, cardiac mass increased from P1 to
P28 primarily due to an increase in CM size rather than in
number (Fig. 1c, d). Interestingly, we found that miR-128
expression was signiﬁcantly increased during heart development
(Fig. 1e). Furthermore, the level of miR-128 was found to be
signiﬁcantly elevated in P7 and P28 hearts compared with P1
hearts. In order to examine whether the postnatal upregulation of
miR-128 occurs speciﬁcally in the CMs, we isolated CMs from P1
and P28 hearts, respectively, and found signiﬁcantly higher
expression of miR-128 in P28 CMs when compared with P1 CMs
(Fig. 1f). Moreover, the expression of miR-128 in CMs was sig-
niﬁcantly higher than in non-CMs (e.g., cardiac ﬁbroblasts, CFs)
(Fig. 1g). These data indicate a potential role for miR-128 in
regulating CM proliferation.
Overexpression of miR-128 impairs cardiac homeostasis. To
specify the function of miR-128 in the heart, a mouse model was
generated in which miR-128 expression was under control of the
α-myosin heavy chain (α-MHC) promoter that was under tem-
poral regulation by doxycycline (Dox). This “Tet-off” transgenic
mouse (α-MHC-tTA; miR-128TetRE) was produced by crossing α-
MHC-tTA mice with miR-128TetRE mice (Supplementary
Fig. 2A). In α-MHC-tTA; miR-128TetRE mice, the TetRE portion
of tTA can bind to the TetO sequences after Dox withdrawal, and
subsequently induce the CM-speciﬁc overexpression of miR-128
(designated as miR-128OE mice) in deﬁned temporal windows
(Fig. 2a and Supplementary Fig. 2B). In general, induced trans-
gene expression begins during the second week of Dox with-
drawal due to the slow clearance of Dox from tissues16–18.
Withdrawal of Dox from miR-128OE fetuses starting at embryo-
nic day 6 (E6) resulted in signiﬁcant induction of miR-128 in
miR-128OE hearts at the P1 neonatal stage as determined by
qPCR (Fig. 2b). At P1, the explanted hearts from miR-128OE mice
were markedly enlarged (Fig. 2c) compared with hearts from
miR-128TetRE mice (Control mice, designated as Ctrl). The higher
heart-to-body weight ratios (HW/BW) of miR-128OE mice rela-
tive to Ctrl showed a progressive increase in heart mass (Fig. 2d).
Morphologically, CM size was measured by staining with wheat
germ agglutinin (WGA), which showed that miR-128OE CMs
were signiﬁcantly larger than Ctrl CMs (Fig. 2e, f), implying the
development of cardiac hypertrophy. Cardiac function analysis
from miR-128OE mice at P1 by echocardiography (Fig. 2g)
showed a reduction of left ventricular (LV) ejection fraction (EF)
and fractional shortening (FS), parameters of cardiac contractile
function, when compared with Ctrl mice. In contrast, Dox
treatment did not induce cardiac dysfunction in Ctrl mice
(Supplementary Fig. 2C).
To explore the cellular mechanisms underlying the observed
hypertrophy, heart sections were immunostained to assess
proliferation and apoptosis. The miR-128OE hearts displayed
diminished proliferation of CMs based on the reduced number of
Ki67+ CMs compared with Ctrl (Fig. 2h, i). However, there was
no signiﬁcant increase in apoptotic CMs in miR-128OE hearts
when assessed by TUNEL staining (Supplementary Fig. 2D).
To study the role of miR-128 in heart development, miR-128OE
mice were mated in the absence of Dox (Supplementary Fig. 2E).
Assessment of miR-128 level by qPCR conﬁrmed its marked
overexpression by E10.5 in the hearts of miR-128OE mice
(Supplementary Fig. 2F). These miR-128OE mutant mice
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displayed enlarged heart chambers, myocardial ﬁbrosis, CM
hypertrophy, and impaired LV systolic heart function at P28
(Supplementary Fig. 2G–I). Moreover, KEGG pathway analysis
showed that oxidative phosphorylation, metabolism, hyper-
trophic cardiomyopathy, and dilated cardiomyopathy pathways
were enriched in miR-128OE hearts. Concomitantly, cell cycle and
DNA replication pathways were suppressed in miR-128OE hearts
(Supplementary Fig. 3). Taken together, these data indicate that
CM-speciﬁc overexpression of miR-128 induces early CM cell
cycle exit, compensatory pathological growth of CM (hypertro-
phy), and impaired cardiac homeostasis.
Deletion of miR-128 stimulates postnatal CM proliferation.
Having established a correlation between miR-128 overexpression
and inhibition of CM proliferation, we asked whether loss of miR-
128 is causal for CM proliferation. In vitro when miR-128 was
knocked down using a speciﬁc miR-128 inhibitor (designated as
Anti-miR-128) (Supplementary Fig. 4A), the neonatal CMs
became dedifferentiated after 7 days. Loss of the CM differ-
entiated state was based on sarcomere disassembly4 assessed by
immunostaining for cardiac troponin T (cTnT), a marker for
sarcomere integrity (Supplementary Fig. 4B–C). Consistent with
sarcomere disassembly, expression of sarcomere genes (Tnnt2
and Myh6) was reduced (Supplementary Fig. 4D). While pro-
moting loss of differentiation, silencing of miR-128, did not
induce apoptosis in these cells (Supplementary Fig. 4E).
The effect of miR-128 knockdown on CM proliferation was
then examined using phosphorylated histone 3 (pH3, a marker of
mitosis) and Aurora B kinase (a marker of cytokinesis). In
addition to inducing dedifferentiation, silencing of miR-128 (anti-
miR-128 CMs) increased the number of mitotic CMs compared
with control CMs (Ctrl) as determined by immunostaining for
pH3 (Supplementary Fig. 4F). Expression of Aurora B kinase was
markedly elevated in Anti-miR-128 CMs (Supplementary Fig. 4G).
We also found a signiﬁcant increase in the number of 5-ethynyl-2
´-deoxyuridine (EdU) positive CMs in the Anti-miR-128 group
indicative of elevated DNA replication (Supplementary Fig. 4H).
Importantly, an increased level of GATA4 (a marker for
dedifferentiated CMs8), was observed in Anti-miR-128 CMs
(Supplementary Fig. 4I).
Given the evidence that silencing of miR-128 induces CM
proliferation in vitro, we next preceded to determine the effects
that deletion of miR-128 would have on CM proliferation in vivo.
Cardiac-speciﬁc conditional miR-128 knockout mice were
generated by crossing miR-128ﬂox/ﬂox (miR-128ﬂ/ﬂ) mice (Sup-
plementary Fig. 5A) with Nkx2.5Cre mice, resulting in cardiac-
speciﬁc deletion of miR-128 during cardiogenesis (Nkx2.5Cre;
miR-128ﬂ/ﬂ mice, designated as miR-128−/−) (Supplementary
Fig. 5B). Hearts from miR-128ﬂ/ﬂ (Control mice, Ctrl) and miR-
128−/− mice were harvested and analyzed at P7, at the time when
most CMs have exited the cell cycle and become post-mitotic6,7.
Downregulation of miR-128 in hearts from miR-128−/− mice was
conﬁrmed by qPCR (Fig. 3a, b). By E10.5, miR-128−/− hearts
exhibited marked downregulation of miR-128. Phenotypic
characterization of miR-128−/− mice at P7 demonstrated that
heart size (Fig. 3c) and heart function by echocardiography
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Fig. 1 MiR-128 increases as the heart progresses from neonate to adult. a Evaluation of wild-type mouse cardiomyocyte (CM) proliferative activity using
Ki67 immunostaining at postnatal day 1 (P1), P7, and P28. Scale bars, 25 µm. b Percentage of CM Ki67+/cTnT+ in P1, P7, and P28 hearts (n= 5 mice for
each time point, ~600 CMs/heart). c Wheat germ agglutinin (WGA) staining of P1, P7, and P28 hearts. Scale bars, 25 µm. d Quantiﬁcation of CM size in
P1, P7, and P28 hearts stained with WGA (n= 5 mice for each time point, ~250 CMs/heart). e Evaluation of miR-128 expression level during heart
development using qPCR analysis, including embryonic day 14.5 (E14.5), E19.5, P1, P3, P7, P14, and P28 hearts (n= 5). f qPCR analysis of miR-128
expression in neonatal (P1) and adult (P28) CMs (n= 5). g Comparison of miR-128 expression by qPCR in cardiac ﬁbroblast (CF) and CMs (n= 5).
Statistical signiﬁcance was calculated using ANOVA in b, d and Student’s t-test in f, g. Data are represented as means± SEM. *P< 0.05
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(Fig. 3d) were unaffected by miR-128 deletion. Although the heart
weight-to-body weight ratio (HB/WB) of miR-128−/− and Ctrl
mice at P7 was similar (Fig. 3e), the CMs in miR-128−/− hearts
were smaller (Fig. 3f). This could indicate an increased number of
CMs in these hearts due to persistent proliferation resulting from
miR-128 deletion. To test this proposition, CMs were stained with
Ki67 to assess the number of cycling cells. The results showed that
loss of miR-128 resulted in a striking increase in CM proliferation
(Fig. 3g, h). Sarcomere disassembly, a characteristic of CM
dedifferentiation and proliferation, was also prominent in miR-
miR-128
E6
Dox
(–) Dox Analysis
0
2
4
6
m
iR
-1
28
(re
lat
ive
 ex
pre
ss
ion
) *
Ctrl miR-128OE
a b
c d e
 f
-MHC tTA
(–) Dox Dox
miR-128TetO-Pr
-MHC-tTA; miR-128TetRE
(miR-128 OE)
miR-128 ON
0
1
2
3 *
CM
 s
ize
(re
lat
ive
)
Ctrl
miR-128OE
M
-m
od
e 
vie
w
Ctrl miR-128OE
Lo
ng
 a
xis
 2
D 
vie
w Di
as
to
le
Sy
st
ol
e
g h i
Ctrl
miR-128OE
Ctrl
miR-128OE
P1 neonate
Ctrl miR-128OE
0
2
4
6
8
H
W
/B
W
 (m
g/g
)
*
Ctrl
miR-128OE
P1 neonate
P1 neonate
0
5
10
15
20
Ki
67
+
 
CM
 (%
)
* VS
0
5
10
15
Ki
67
+
 
CM
 (%
)
* RV
LV
Ctrl miR-128OE
P1 neonate
cT
nT
D
AP
I
P1 neonate
VS
RV
0
0.2
0.4
0.6
0.8
1
LV
D
s 
(m
m)
*
0
0.5
1
1.5
2
LV
D
d 
(m
m)
NS
30
50
70
90
110 *
EF
 (%
)
30
35
40
45
50
55
60 *
FS
 (%
)
0
5
10
15
20
Ki
67
+
 
CM
 (%
)
*
LV
cT
nT
D
AP
I
cT
nT
D
AP
I
Ctrl miR-128OE
P1
Ki
67
   
W
G
A
Ki
67
 
Ki
67
 
t
Fig. 2 Overexpression of miR-128 in cardiomyocytes impairs cardiac homeostasis. a Schematic showing the generation of mice that overexpress CM-
speciﬁc miR-128 after doxycycline (Dox) withdrawal. Control mice were miR-128TetRE mice, and miR-128OE mice were α-MHC-tTA; miR-128TetRE mice. b
Schematic of experimental design for CM-speciﬁc overexpression of miR-128 at P1 (left panel). Right panel shows the qPCR analysis of miR-128 expression
in Ctrl and miR-128OE mice (n= 5). c Gross morphology (upper panel) and Masson trichrome staining (lower panel) of hearts at P1. Scale bars, 0.25 cm
(upper panel); 1 mm (lower panel). d Heart weight (HW) to body weight (BW) ratio of P1 mice (n= 8). e Wheat germ agglutinin (WGA) staining of P1
neonatal hearts. Scale bars, 25 µm. f Quantiﬁcation of CM size as determined by WGA staining (n= 8 mice, ~200 CMs/heart). g Heart function analyzed
by echocardiography in P1 mice as measured by left ventricular end-diastolic diameter (LVDd), LV end-systolic diameter (LVDs), ejection fraction (EF), and
fraction shortening (FS) (n= 6). h Evaluation of CM proliferative activity by Ki67 immunostaining in Ctrl and miR-128OE hearts. Scale bars, 25 µm (yellow);
10 µm (white). i Quantiﬁcation data of CM proliferative activity by Ki67 staining in Ctrl and miR-128OE hearts (n= 6 mice, ~800 CMs/heart). Statistical
signiﬁcance was calculated using Student’s t-test. Data are represented as means± SEM. *P< 0.05
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03019-z
4 NATURE COMMUNICATIONS |  (2018) 9:700 |DOI: 10.1038/s41467-018-03019-z |www.nature.com/naturecommunications
128−/− hearts compared with the Ctrl hearts (Fig. 3g, i, and j). In
addition to the CMs with disassembled sarcomeres, there was a
signiﬁcantly higher number of Ki67-positive cells in the
miR-128−/− hearts, and with no obvious CM apoptosis in the
miR-128−/− hearts (Fig. 3k). By EdU incorporation assay
(Fig. 3l–o), we also found a signiﬁcant increase in the number
of EdU+ CMs in miR-128−/− hearts compared with Ctrl at P14
(Fig. 3l, m) as well as at P21 (Fig. 3n, o). Nevertheless, these mice
developed normally to adulthood and did not exhibit any cardiac
dysfunctions (Supplementary Fig. 6A, B). These data suggest that
tissue-speciﬁc deletion of miR-128 deletion is sufﬁcient to extend
the postnatal CM proliferation window.
MiR-128 deletion reconﬁgures cell cycle gene expression. RNA-
seq was performed on control (Ctrl) and miR-128OE hearts (P7)
to identify the putative target genes of miR-128 responsible for
cell cycle regulation. By comparing the downregulated mRNAs
identiﬁed in miR-128OE hearts relative to Ctrl hearts with all
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possible predicted candidate miR-128 target genes19, we found 87
genes that contained the predicted binding site at the 3′UTR
(Supplementary Fig. 7A). Gene Ontology (GO) PANTHER
Analysis was then performed to identify the affected cellular
biological processes. The leading biological category was ‘‘cellular
process’’ category, with nearly 28.7% of all associated genes (GO:
0009987, Supplementary Fig. 7B). A further subgroup analysis of
the ‘‘cellular process’’ indicated the potential for miR-128 to affect
multiple pathways that are related to regulation of the cell cycle,
cell communication, and cellular component movement (Sup-
plementary Fig. 7B). Moreover, the analysis of genes down-
regulated in miR-128OE showed statistically signiﬁcant
enrichment of genes downregulated after small interfering RNA
(siRNA) inhibition of components of polycomb repressive com-
plex 2 (PRC2), Suz12 in particular (Supplementary Fig. 7C).
PRC2 is a chromatin modiﬁer complex that is crucial for orga-
nogenesis20. Perturbation of the epigenetic landscape by ablation
of PRC2 subunits during early cardiac development inhibits CM
proliferation, and eventually leads to fatal cardiac malforma-
tions21. Computational analysis showed that Suz12 was a pre-
dicted target gene of miR-128 (Fig. 4a). In contrast to neonatal
hearts, the protein levels of SUZ12 were lower in the adult heart
(where the CM proliferation ability is quite limited) (Fig. 4b, c),
paralleling the upregulation of miR-128. These data suggest that
miR-128 may regulate CM proliferation via its intercation
with Suz12 .
To investigate whether miR-128 regulates Suz12 expression,
mouse neonatal CMs were transfected with a negative control
(Ctrl), a mimic of miR-128 (miR-128), or an inhibitor of miR-128
(Anti-miR-128) and assessed for the level of SUZ12 by western
blot analysis. Overexpression of miR-128 signiﬁcantly reduced the
protein level of SUZ12, whereas inhibition of miR-128 led to its
increased expression (Fig. 4d, e). To further test whether miR-128
regulates Suz12 expression, we constructed a vector containing
luciferase reporter with a DNA sequence encoding the complete
3′UTR from mouse Suz12 (designated as WT), and a mutated
vector (designated as Mut) containing mismatches in the
predicted miR-128-binding site in the 3′UTR (Fig. 4f). Co-
transfection of HEK293T cells with the Suz12 3′UTR plasmid
(WT) and miR-128 mimic resulted in a signiﬁcant decrease in
luciferase activity compared with cells co-transfected with the
negative control or the mutated 3′UTR target sequence (Mut),
indicating that Suz12 is a direct target of miR-128, consistent with
a previous report22.
To better deﬁne how the interaction between miR-128 and
Suz12 might mediate cell proliferation in vivo, we ﬁrst analyzed
the expression of cell cycle-related genes in miR-128−/− hearts at
P7 and found that expression of SUZ12, cyclin E and cyclin-
dependent Kinase 2 (CDK2) was elevated in miR-128−/− P7 hearts
compared with hearts from control mice (Ctrl) while the CDK
inhibitor (CDKi) p27 was downregulated (Fig. 4g, h). As SUZ12
can modulates the functionality of enhancer of zeste homolog 2
(EZH2), which catalyzes the formation of H3K27me3 (a
transcriptional repressive mark)23, we performed chromatin
immunoprecipitation (ChIP)-qPCR assay and found that
SUZ12, EZH2, and H3K27me3 were signiﬁcantly enriched on
the p27 promoter in miR-128−/− hearts as compared to Ctrl
(Fig. 4i). These data indicate that the downregulation of p27
induced by miR-128 deletion is attributed, at least in part, to
PRC2 mediated gene silencing.
To investigate whether regulation of Suz12 signaling after miR-
128 deletion is responsible for the enhanced proliferation in CMs,
loss of function study was performed using siRNA against Suz12.
In vitro, direct inhibition of Suz12 by siRNA (si-Suz12) in
cultured miR-128−/− neonatal CMs reversed the pro-proliferative
effect conferred by miR-128 deletion (miR-128−/−), as evidenced
by a signiﬁcant decrease in the number of Ki67+ CMs in the si-
Suz12 group in contrast to control group (si-Ctrl) (Fig. 5a–c). To
further validate that the Suz12-pathway is a major functional
mediator of miR-128 effects, we injected miR-128−/− mice
(intraperitoneal (i.p.) injection) with si-Suz12 or si-Ctrl at P1,
P3, P5, and harvested the hearts at P7 (Fig. 5d). Knockdown of
Suz12 in vivo signiﬁcantly induced CM hypertrophy (Fig. 5e) and
impaired CM proliferation by decreasing the number of EdU+
CMs (Fig. 5f). Moreover, there was a signiﬁcant increase in the
level of p27 and decrease of Cyclin E and CDK2 expression in the
si-Suz12 group when compared with si-Ctrl treated hearts
(Fig. 5g, h). These data indicate that miR-128 deletion stimulates
proliferation of CMs, in part through epigenetic modulation of
cell cycle-related genes via targeting of Suz12 (Fig. 5i).
Overexpression of miR-128 inhibits cardiac regeneration. An
apex resection (AR) model in neonatal mice at P1 (Supplemen-
tary Fig. 8A) was developed to enable assessment of temporal
gene expression during cardiac regeneration. Histological analysis
veriﬁed that by day 7 post AR, the initial large blood clot in the
apex had been replaced by newly formed CMs and limited ﬁbrotic
tissue (Supplementary Fig. 8B). Also at day 7 post AR, genes
associated with cell proliferation were signiﬁcantly activated,
whereas miR-128 expression was signiﬁcantly diminished (Sup-
plementary Fig. 8C, D). These data imply that expression level of
miR-128 is associated with neonatal heart regeneration.
A miR-128OE mouse model in which miR-128 was over-
expressed in a CM-speciﬁc and temporally controlled (by Dox
withdrawal) manner (Fig. 6a) was used to test whether miR-128
regulates cardiac regenerative capacity in neonatal mice. The
miR-128OE mice and control miR-128TetRE mice (Ctrl) were
subjected to AR at P1, and hearts from both groups were
examined histologically. At 21 days post AR, the miR-128OE
hearts showed left ventricle dilation and defective regeneration
compared with Ctrl groups (Fig. 6b). The miR-128OE hearts
Fig. 3 Cardiac miR-128 deletion promotes postnatal CM proliferation in vivo. a Schematic diagram depicting the generation of cardiac-speciﬁc miR-128
knockout (miR-128−/−) mice. Control mice were miR-128ﬂ/ﬂ mice, and miR-128−/− mice were Nkx2.5Cre; miR-128ﬂ/ﬂ mice. b The expression level of miR-128
during heart development (n= 6) analyzed by qPCR, including embryonic day 10.5 (E10.5), E14.5, postnatal day 7 (P7), and P28. c Masson trichrome
staining of mouse hearts at P7. Scale bars, 2.0 mm. d Comparison of cardiac function between Ctrl and miR-128−/− hearts analyzed by echocardiography at
P7, and measured by EF and FS (n= 6). eMeasurement of HW to BW ratio in Ctrl and miR-128−/− mice (n= 6). f Evaluation of CM size in P7 Ctrl and miR-
128−/− hearts assessed by WGA and cardiac troponin T (cTnT) staining (n= 5 mice, ~250 CMs/heart). Scale bars, 50 µm (yellow); 10 µm (white). g
Assessment of CM proliferative activity and sarcomere structure in P7 hearts by immunoﬂuorescence of cTnT and Ki67. Arrows indicate Ki67-positive
CMs with sarcomere disassembly. Scale bars, 500 µm (yellow); 25 µm (white). h–j Quantiﬁcation of Ki67+ CMs, sarcomere disassembled CMs and Ki67+
disassembled CMs (n= 4860 CMs pooled from six mice). k CM apoptosis analyzed by TUNEL staining. l Schematic diagram depicting the protocol for EdU
intraperitoneal (i.p.) injection at P7 mice to label proliferating CMs in vivo. m Analysis of CM proliferation by EdU incorporation assay in Ctrl and miR-128
−/− hearts at P14 (n= 6 mice, ~250 CMs/heart). Scale bars, 50 µm. n Schematic diagram depicting the protocol for EdU intraperitoneal (i.p.) injection at
P14 to label proliferating CMs in vivo. o Comparison of EdU+ CMs in Ctrl and miR-128−/− hearts at P21 (n= 6 mice, ~200 CMs/heart). Statistical
signiﬁcance was calculated using Student’s t-test. Data are represented as means± SEM. *P< 0.05
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showed fewer proliferating CMs, as quantiﬁed by the decreased
number of EdU+ CMs in the injured apex and border area
(Fig. 6c, d), and a greater extent of CM hypertrophy (Fig. 6e). In
addition, systolic function was signiﬁcantly impaired in the
miR-128OE group relative to Ctrl group (Fig. 6f, g). These ﬁndings
suggest that inhibition of CM proliferation by miR-128 over-
expression can impair cardiac regeneration in a neonatal mouse
model.
Deletion of miR-128 promotes adult cardiac regeneration. To
investigate whether loss of miR-128 in the adult is capable of
promoting CM proliferation, cardiac-speciﬁc, tamoxifen (TAM)
inducible miR-128 knockout mice were then generated by
crossing α-MHCMerCreMer mice with miR-128ﬂ/ﬂ mice (Fig. 7a).
TAM was administered at P21 to induce the miR-128 knockout at
the adult stage. The adult miR-128 deleted mice were designated
iKO, and the knockout was validated by qPCR. The heart weight-
to-body ratio (HB/WB) was unchanged in iKO mice. Staining
with WAG, however, showed that the size of the iKO CMs was
smaller than the control CMs (Fig. 7b–d), suggesting that loss of
miR-128 in the adult heart increases the number of CMs. This
increase in CM number following miR-128 deletion was further
conﬁrmed by analysis of EdU incorporation into CMs (Fig. 7e).
Furthermore, the total number of adult CMs and percentage of
mono-nucleated CMs was signiﬁcantly increased in iKO hearts
2 weeks after TAM-induced miR-128 deletion (Fig. 7f, g).
To determine whether cells in the myocardial lineage
dedifferentiate following deletion of miR-128, a TAM inducible
dual-lineage tracing system was generated by crossing α-
MHCMerCreMer mice with miR-128ﬂ/ﬂ mice followed by crossing
with Rosa26-tdTomato reporter mice to produce α-
MHCMerCreMer; miR-128ﬂ/+; R26R-tdTomato mice (designated
as iKO-tdTomato) (Fig. 7h). In these transgenic mice, the pre-
existing CMs with miR-128 knockout were labeled red (tdTo-
mato, red ﬂuorescence) following TAM administration. After
TAM-induced miR-128 deletion (Fig. 7i), the α-MHC myocardial
lineage-positive CMs in iKO-tdTomato mouse displayed a
disorganized sarcomere structure and reduced sarcomere-
related gene expression compared with control mice (α-
MHCMerCreMer; R26R-tdTomato, designated as Ctrl-tdTomato)
(Fig. 7j, k). There was no observable apoptosis in hearts from
iKO-tdTomato mice (Supplementary Fig. 9A, B). There was,
however, increased expression of genes associated with cell
proliferation (Nuspa1, Racgap1 and Myh10) and fetal genes
associated with negative regulation of CM differentiation (Nppa
and Nppb) in iKO-tdTomato hearts detected by qPCR (Fig. 7k).
Importantly, in iKO mice, cardiac morphology remained
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unchanged and heart functions were normal (Supplementary
Fig. 9C, D). These results indicate that deletion of miR-128 in the
adult heart results in dedifferentiation and cell cycle re-entry of
CMs, but has no impact on heart function.
To determine whether induction of cardiac proliferation
following miR-128 deletion in adult mice is sufﬁcient to allow
adult heart repair following MI, adult iKO mice were subjected to
permanent ligation of the left anterior descending (LAD)
coronary artery. One day after MI, we administered TAM to
delete miR-128 in CMs (Fig. 8a). Analysis of iKO hearts at day 7
after TAM injection showed that the expression of miR-128
target SUZ12 was signiﬁcantly increased, accompanied by
downregulation of the p27 and upregulation of Cyclin E and
CDK2 (Fig. 8b). Moreover, we observed a signiﬁcant increase in
the number of Aurora B-positive CMs (Fig. 8c), and in EdU
positive CMs in the iKO hearts (Fig. 8d, e). These changes were
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associated with reduced cardiac ﬁbrosis in the iKO hearts
(Supplementary Fig. 10B). In addition, analysis of sarcomere
structures in iKO hearts revealed robust dedifferentiated cardiac
muscle in border areas and remote areas (Fig. 8d). Although
it was previously reported that miR-128 regulates apoptosis
by targeting peroxisome proliferator-activated receptor gamma
(Pparg)24, we found no signiﬁcant differences in either
PPARγ expression or apoptosis in iKO hearts when compared
to Ctrl hearts at day 7 after TAM injection (Supplementary
Fig. 10C, D).
In addition to dedifferentiation and enhanced proliferation,
iKO hearts showed signiﬁcantly less ﬁbrosis as compared to Ctrl
groups 4 weeks after MI (Fig. 9a, b). Similarly, diminished cardiac
function was signiﬁcantly reversed in iKO mice, as evidenced by
increased EF and FS after MI when compared with the Ctrl
animals (Fig. 9c, d). Cardiac remodeling was also signiﬁcantly
reversed in iKO mice with reduced LVDd and LVDs (Fig. 9d).
Collectively, these data indicate that inhibition of miR-128
promotes CM proliferation and improves endogenous cardiac
regeneration after MI (Fig. 10).
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Discussion
The application of direct activation of pre-existing CM pro-
liferation is emerging as one of the most promising strategies in
cardiac regenerative medicine5,25,26. Dissecting the mechanisms
by which adult CMs exit the cell cycle arrest is fundamental for
therapeutic manipulation to stimulate endogenous CM pro-
liferation in the adult myocardium. Although several CM cell
cycle mediators have been identiﬁed5,25, manipulation of these
genes is insufﬁcient for full recovery of heart function in response
to injury. It is, therefore, essential to discover novel therapeutic
targets that activate endogenous CM proliferation and recovery of
cardiac function after damage.
Involvement of miRNAs has been invoked as one mechanism
underlying regulation of cell proliferation. In this report, we
propose a model in which inhibition of miR-128 in vivo promotes
cardiac regeneration by activating CM proliferation. We
demonstrate that (1) The upregulation of miR-128 in heart tissue
is associated with the cell cycle exit of CMs during postnatal
growth. (2) Cardiac-speciﬁc overexpression of miR-128 leads to
premature cell cycle arrest and cardiac hypertrophy. (3) miR-128
regulates several cell cycle-related genes such as p27 by targeting
Suz12. (4) Overexpression of miR-128 inhibits CM proliferation
and neonatal heart regeneration. (5) Inhibition of miR-128 pro-
longs the postnatal CM proliferation window and enhances the
cardiac regenerative capacity of adult heart.
As a neuronal-enriched miRNA15,27, miR-128 is associated
with central nervous system development28,29 and is down-
regulated in gliomas30. Downregulation of miR-128 accelerates
glioma-initiating neural stem cell proliferation and contributes to
the development of gliomas31. Recent research has demonstrated
the involvement of miR-128 in cardiac repair of lower vertebrates
such as the newt32 and showed that miR-128 inhibitors enhanced
the proliferation (hyperplasia) of non-CMs and extracellular
matrix deposition but had no effect on CMs, which was contrary
to our current ﬁnding in mice. The discrepancy is potentially due
to the use of different animal models with complex heart cell
phenotypes. However, these ﬁndings bring important informa-
tion into the translational study of mammals. In our study, miR-
128 was revealed for the ﬁrst time to be a negative regulator of the
CM cell cycle when using a cardiac lineage-restricted transgenic
mouse model. Deletion of miR-128 prolonged the postnatal CM
proliferation window, as evidenced by pronounced sarcomere
disassembly and proliferative markers including pH3, Ki67,
Aurora B, and EdU. Normal growth of developing heart requires
a proper balance between cycling cells and cells that exit the cycle.
Disturbance in this balance is associated with hypertrophy33–35
that is deﬁned as cell enlargement due to an increase in protein or
RNA content without DNA replication or cytokinesis. RNA-seq
revealed that the downstream genes of miR-128 are involved in
pathways of DNA replication, cell cycle, hypertrophic cardio-
myopathy, or dilated cardiomyopathy. Transgenic mice over-
expressing miR-128 displayed premature cell cycle exit, cardiac
hypertrophy, and cardiac dysfunction. Further analysis is
underway to explore the association of miR-128 activation in
pathogenesis of congenital heart disease involving abnormalities
of myocardial growth.
Cell cycle exit in CMs is accompanied by downregulation of
positive cell cycle regulators and upregulation of CDKIs36.
Among the target genes regulated by miR-128, is Suz12 whose
expression is signiﬁcantly lower in adult hearts. This ﬁnding
suggests that Suz12 plays a primary role in CM cell cycle reg-
ulation including neonatal cell cycle withdrawal and the later
stages of heart development. This study demonstrated that
knockdown of Suz12 resulted in a reduction of CM proliferation,
which is consistent with its function in gene silencing23,37 and
playing a fundamental role in mouse development38. Accom-
panied with the upregulation of SUZ12 protein, downregulation
of negative cell cycle regulators (such as p27) and upregulation of
downstream positive cell cycle regulators such as Cyclin E and
CDK2 were observed in the miR-128-deﬁcient heart. P27, as a
major member of CIP/KIP CDKI family, has been implicated in
CM cell cycle arrest39 and its deletion promotes CM entry into S-
phase40–42. P27 can also negatively modulate the activity of Cyclin
E-dependent kinase36,43, a requirement for entry of cells into S-
phase44. Our data suggest that elimination of miR-128 might
activate cell cycle-related genes, in part through SUZ12-regulated
histone modiﬁcation, thereby promoting CM proliferation. Since
SUZ12 is a chromatin-associated protein that is broadly dis-
tributed, it is likely that it regulates other genes involved in CM
proliferation. Thus, it would be informative to perform ChIP-seq
and RNA-seq to systemically identify target genes of SUZ12 to
better understand how SUZ12 modulates the activity of EZH2,
the enrichment of H3K27me3 and transcriptional output. Recent
studies on the role played by the nervous system in endogenous
heart regeneration are yielding mechanistic insights. For instance,
direct mechanical denervation impairs heart regeneration in
mammals, but is restored upon administration of neuregulin-1
(NRG1) and nerve growth factor (NGF). Evidence from studies in
zebraﬁsh and mice has revealed that NRG1-Erbb signaling is
crucial for proper heart formation, CM proliferation, and mor-
phology45–47. Interestingly, our RNA-seq data set revealed
downregulation of Erbb2 (NRG1 co-receptor) in miR-128OE
heart. However, it remains to be determined whether the effects
of miR-128 on cardiac regeneration following injury are mediated
in part by its activity in the nervous system. Using a gain-of-
function genetic approach in our neonatal cardiac injury model,
we found that miR-128 overexpression inhibited CM proliferation
and neonatal heart regeneration. These ﬁndings highlight the
involvement of miR-128 in the pathway that arrests CM pro-
liferation and cardiac regeneration after birth. To assess the
potential therapeutic beneﬁt of miR-128 inhibition in MI, we
generated a cardiac-speciﬁc, tamoxifen-inducible miR-128
knockout mouse model. The effect of miR-128 deletion on the
cell cycle was evident in adult stages, when adult CMs are fully
Fig. 7 MiR-128 deletion promotes proliferation of adult CMs. a Schematic diagram depicting the protocol of tamoxifen (TAM)-inducible miR-128 deletion
(iKO) in adult hearts (P28). Control (Ctrl) mice were miR-128ﬂ/ﬂ mice, and iKO mice were α-MHCMerCreMer; miR-128ﬂ/ﬂ mice. b WGA staining in adult
control and iKO hearts. Scale bars, 50 µm. cMeasurement of HW to BW ratio in control and iKO hearts (n= 6). d Quantiﬁcation of CM size determined by
WGA staining (n= 6 mice, ~150 CMs/heart). e Evaluation of CM proliferation by EdU incorporation (n= 1130 CMs pooled from ﬁve mice). Scale bars, 25
µm. f Representative images of isolated adult CMs in control and iKO hearts. Scale bars, 100 µm. g Comparison of CM number in hearts from control and
iKO mice. Approximately 2000 CMs were counted per sample, three independent samples per group. h Schematic diagram for the TAM-inducible dual-
lineage tracing protocol for the mouse models. Control (Ctrl-tdTomato) mice were α-MHCMerCreMer; RosatdTomato. The iKO-tdTomato mice were
αMHCMerCreMer; miR-128ﬂ/ﬂ; RosatdTomato. i qPCR analysis of miR-128 expression in Ctrl-tdTomato and iKO-tdTomato hearts (n= 5). j Analysis of in vivo
sarcomere structure of hears from Ctrl-tdTomato and iKO-tdTomato mice by immunoﬂuorescence staining of cTnT (n= 5). Scale bars, 10 µm. k Expression
of sarcomere genes, fetal genes, and genes associated with cell proliferation analyzed by qPCR in adult hearts from Ctrl-tdTomato and iKO-tdTomato mice
(n= 6). Statistical signiﬁcance was calculated using Student’s t-test in b, d, e, g, i, and k. Data are represented as means± SEM. *P< 0.05. NS, not
signiﬁcant
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differentiated and quiescent and their ability to divide is quite
limited. Using genetic lineage tracing, our results provide proof-
of-concept that pre-existing CMs rather than progenitor cells are,
in fact, the target cells that respond to miR-128 deletion during
regeneration after cardiac damage. These adult CMs lacking miR-
128 can be ‘‘rejuvenated’’ to an immature stage that allows them
to dedifferentiate and enter a proliferative state, an endogenous
program for natural heart regeneration that occurs in the zeb-
raﬁsh and neonatal mice in response to injury48. Of particular
interest, the changes in cellular capabilities induced by loss of
miR-128 result in increased cellular plasticity that allows sig-
niﬁcant anatomical and functional capacity upon injury, but does
not impair heart function under normal conditions.
In summary, our study demonstrates that we can activate
endogenous CM proliferation by targeting miR-128, and that this
strategy is a potentially valuable approach for inducing myo-
cardial regeneration, and may lead to major therapeutic advances
in the treatment of human heart disease.
Methods
Laboratory animals. All research protocols conformed to the Guidelines for the
Care and Use of Laboratory Animals published by the National Institutes of Health
(National Academies Press, eighth edition, 2011). All animal use protocols and
methods of euthanasia (pentobarbital overdose followed by thoracotomy) used in
this study were approved by the University of Cincinnati Animal Care and Use
Committee. An independent review and approval of cell and chemical drug used in
this study was conducted by the Institutional Biosafety Committee (IBC). Mice
were maintained on a C57BL/6 background and their genotype was determined by
PCR from tail DNA. Both male and female mice were randomized in different
experiment groups.
Generation of mice with conditional overexpression of miR-128. A construct
was engineered for knockin of the miR-128 (miR-128-3p) gene into the Rosa26
locus. Rosa26 genomic DNA fragments (~1.1 kb and ~4.3 kb 5′ and 3′ homology
arms, respectively) were ampliﬁed from C57BL/6 BAC DNA, cloned into the
pBasicLNeoL vector sequentially by in-fusion cloning, and conﬁrmed by sequen-
cing. The miR-128 gene, under the control of tetO-minimum promoter, was also
cloned into the vector between the two homology arms. In addition, the targeting
construct also contained a loxP sites ﬂanking the neomycin resistance gene cassette
for positive selection and a diphtheria toxin A (DTA) cassette for negative selec-
tion. The construct was linearized with ClaI and electroporated into C57BL/6N ES
cells. After G418 selection, seven-positive clones were identiﬁed from 121 G418-
resistant clones by PCR screening. Six-positive clones were expanded and further
analyzed by Southern blot analysis, among which four clones were conﬁrmed with
correct targeting with single-copy integration. Correctly targeted ES cell clones
were injected into blastocysts, and the blastocysts were implanted into pseudo-
pregnant mice to generate chimeras by Cyagen Biosciences Inc. Chimeric males
were bred with Cre deleted mice from Jackson Laboratories to generate neomycin-
free knockin mice. The correct insertion of the miR-128 cassette and successful
removal of the neomycin cassette were conﬁrmed by PCR analysis with the primers
listed in Supplementary Table 1.
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Fig. 8 MiR-128 deletion promotes adult cardiomyocyte proliferation after MI. a Schematic of the experimental design for assessing adult (12-weeks-old)
cardiac regeneration following MI in TAM-inducible miR-128 knockout (iKO) mice. Control (Ctrl) mice were miR-128ﬂ/ﬂ mice, and iKO mice were α-
MHCMerCreMer; miR-128ﬂ/ﬂ mice. bWestern blot analysis of cell cycle-related gene expression in infarcted hearts at day 7 after TAM administration (n= 3).
c Immunostaining of Aurora B in infarcted hearts at day 14 after TAM administration (n= 5 mice, ~400 CMs/heart). Scale bars, 250 pixel. d Evaluation of
CM proliferation by EdU incorporation assay. Scale bars, 50 µm. e Quantiﬁcation of EdU+ CMs in the Ctrl and iKO hearts at 1 week (1W) and 4 weeks (4
W) post MI (n= 5 mice, ~250 CMs/heart). Statistical signiﬁcance was calculated using Student’s t-test in c, e. Data are represented as means± SEM. *P<
0.05
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Mice with doxycycline-inducible CM-speciﬁc overexpression of miR-128 (miR-
128-3p) were generated by crossing α-MHC-tTA (The Jackson Laboratory) mice
with miR-128TetRE mice, in which tetracycline-responsive transcriptional activator
(tTA) expression is under the control of α-MHC promoter. Doxycycline (Dox,
Harland Laboratories) containing diet was administered to repress transgene
expression.
Generation of mice with a conditional deletion of miR-128. A construct was
engineered for conditional disruption of the miR-128 (miR-128-3p) gene in which a
1.7 kb fragment spanning the miR-128 gene was ﬂanked by two loxP sites. The 1.7
kb fragment, the 5.4 kb left homology arm, and the 2.9 kb right homology arm were
ampliﬁed from C57BL/6 BAC DNA and cloned into the pBasicLFNeoFL vector
sequentially by in-fusion cloning and conﬁrmed by sequencing. In addition to
conditional knockout (cKO) region and homology arms, the targeting construct
also contains Frt sites ﬂanking the neomycin cassette for positive selection and a
DTA cassette for negative selection. The construct was linearized with NotI and
electroporated into C57BL/6N ES cells. After G418 selection, three-positive clones
were identiﬁed from 280 G418-resistant clones by PCR screening. The positive
clones were expanded and further analyzed by Southern blot. The random inte-
gration of extra copies of targeting construct was excluded by hybridization with a
neomycin probe. To generate chimeras, ES cell clones were microinjected into
blastocysts, and the blastocysts were implanted into pseudo-pregnant foster mice
by Cyagen Biosciences Inc. Chimeric males were bred with Flp deleter mice
from Jackson Laboratories to generate neomycin-free ﬂoxed mice. The correct
integration of loxP sites and the successful removal of the neomycin cassette were
conﬁrmed by PCR analysis with the primer listed in Supplementary Table 1.
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Fig. 9 MiR-128 deletion promotes adult cardiac regeneration after MI. a Representative images of Masson trichrome-stained heart section at 28 days after
MI. Serial sectioning was performed at 500 µm intervals. The most signiﬁcant difference between two groups is highlighted by the red box. Scale bars, 1
mm. b Measurement of ﬁbrotic areas in heart sections following MI in control and iKO mice analyzed by Masson trichrome staining. (n= 8). c, d Heart
function analyzed by echocardiography and quantiﬁed by LVDd, LVDs, EF, and FS (n= 6). Control (Ctrl) mice were miR-128ﬂ/ﬂ mice, iKO mice were α-
MHCMerCreMer; miR-128ﬂ/ﬂ mice. Statistical signiﬁcance was calculated using Student’s t-test in b, d. Data are represented as means± SEM. *P< 0.05. NS,
not signiﬁcant
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Cardiac-speciﬁc miR-128 knockout mice (miR-128−/−) were generated by crossing
Nkx2.5Cre (The Jackson Laboratory) mice with miR-128ﬂ/ﬂ mice.
Tamoxifen (TAM) inducible CM-speciﬁc miR-128 knockout mice (iKO) were
generated by crossing α-MHCMerCreMer mice (Tg(α-MHC-cre/Esr*)1Jmk/J, The
Jackson Laboratory) with miR-128ﬂ/ﬂ mice. Induction of Cre recombinase activity
was achieved using two doses of tamoxifen (Sigma, 0.25 mg g−1 body weight)
dissolved in corn oil (Sigma) and administrated intraperitoneally (i.p.) on day 1
and 3.
A dual-lineage tracing system was established to investigate the origin of
regenerated CMs. α-MHCMerCreMer mice were crossed with Rosa26-tdTomato
(R26R-mTmG, The Jackson Laboratory) reporter mice and miR-128ﬂ/ﬂ mice to
generate iKO-mTmG mice (α-MHCMerCreMer;miR-128ﬂ/+;R26R-mTmG) to label
miR-128 null CM with red color following tamoxifen administration. All mice were
maintained on a C57BL/6 background.
RNA-seq and bioinformatics analysis. RNA-seq experiments were performed by
the Genomics, Epigenomics and Sequencing Core (GESC) at the University of
Cincinnati. To analyze differential gene expression, sequence reads were aligned to
the mouse genome (mm10) by using standard Illumina sequence analysis pipeline,
which was performed by The Laboratory for Statistical Genomics and Systems
Biology at the University of Cincinnati.
The sample processing, sequencing, and data analysis were described in
previous publications49,50. Sample tissues were homogenized in 0.6 ml lysis/binding
buffer from the mirVana miRNA Isolation Kit (Thermo Fisher Scientiﬁc, AM1560)
using a Bullet Blender Storm homogenizer (MIDSCI). Total RNA extract was
performed according to the mirVana protocol, and the RNA was eluted with 100 μl
of elution buffer. Quality of RNA was assessed using a 2100 Bioanalyzer (Agilent
Technologies).
RNA-seq reads were processed to remove quality reads and then aligned to the
mouse reference genome using TopHat2 aligner51. Reads aligning to known gene
were counted using Bioconductor packages for next-generation sequencing data
analysis52. The differential expression analysis between miR-128OE hearts and
control samples was performed using the negative binomial statistical model of
read counts as implemented in the edgeR Bioconductor package53. The KEGG
pathways54 and MSigDb gene sets55 enrichment analysis was performed using
LRpath methodology as implemented in the CLEAN package56, and ranked by the
enrichment P-value. Functional enrichment analysis of the genes that are both
downregulated in miR-128OE hearts and are predicted targets of miR-128 is
performed using PANTHER enrichment analysis tool57.
Neonatal CM isolation and culture. Neonatal rat CMs were isolated from ven-
tricles of 1-day-old neonatal Sprague–Dawley rats (Harland) using a neonatal CM
isolation kit (Worthington Biochemical, LK003300) according to the manu-
facturer’s instructions. Neonatal mouse CMs were isolated from 1-day-old (P1)
C57BL/6 mice with a modiﬁed protocol as previously described58. Brieﬂy, after
washing and mincing the neonatal mouse hearts with PBS (without Ca2+, Mg2+)
supplemented with 20 mM BDM (Sigma-Aldrich), tissue fragments were incubated
in the isolation medium (PBS supplemented with 20 mM BDM and 0.0125%
trypsin) with gentle agitation 4 °C overnight. Predigested tissue fragments were
then transferred into the freshly made digestion medium (1.5 mgml−1, collagenase/
dispase mixture, Roche) and incubated for 20 min at 37 °C. The cell suspension was
collected and centrifuged to yield the isolated cell pellets. Cells were plated and
incubated for 2 h in cell culture incubator. The adherent ﬁbroblast were further
cultured and harvested. The non-adherent CMs were re-suspended and cultured in
0.1% gelatin plus with 10 µg ml−1 ﬁbronectin (Sigma-Aldrich, F1141) coated slides
with 68% Dulbecco's Modiﬁed Eagle's Medium (DMEM) high-glucose medium
supplemented with 17% M-199, 4% horse serum (Gibco, 26050088), 10% FBS, and
1% penicillin/streptomycin (hereafter referred to as ‘‘complete-medium’’) at 37 °C
and 5% CO2. After the cells were allowed to adhere for 24 h, miR-128 mimic (50
nM, Dharmacon, C-310957-01-0005), miR-128 inhibitor (50 nM, Dharmacon, IH-
310957-02-0005), or siRNA against Suz12 (50 nM, Dharmacon, L-040180-00-0020)
transfection were performed according to the manufacturer’s instructions. After 48
h, cells were harvested for analysis. Control samples were transfected with an equal
concentration of negative control mimic, inhibitor or siRNA.
Adult CM isolation and culture. Adult mouse CMs were isolated from adult
C57BL/6 mice with a modiﬁed protocol as described59. Brieﬂy, the aorta of the
excised heart was clamped and mounted on a Langendorf apparatus and perfused
with calcium-free perfusion buffer (113 mM NaCl, 4.7 mM KCl, 0.6 mM KH2PO4,
0.6 mM Na2HPO4, 1.2 mM MgSO4, 10 mM Na-HEPES, 12 mM NaHCO3, 10 mM
KHCO3, 0.032 mM phenol red, 30 mM taurine, 10 mM BDM, and 5.5 mM glucose;
pH-7.0.), followed by digestion with 50 ml perfusion buffer containing 15,000 U of
type II collagenase (Roche) and 50 μM CaCl2. Stop digestion when the heart
became slightly pale and ﬂaccid. Then the heart was gently teased into small pieces
with forceps, and triturated with a Pasteur pipette to dissociate individual CM. The
cell suspension was collected and centrifuged to yield CM pellets. The adult mouse
CMs were cultured on laminin (10 µg ml−1, Life technologies, 23017015) coated
slides with AW medium (Cellutron life technologies, m-8034) with 10% FBS.
Luciferase reporter assay. The DNA fragment containing 3′ untranlsted regions
(3′UTR) was ampliﬁed by PCR and cloned into luciferase reporter vector-
psiCHECK2 (Promega, C8021). The reporter vector containing mutant 3′UTR was
generated using a Site-Directed Mutagenesis Kit (New England Biolabs). HEK-293
cells (ATCC, CRL-1573) were transfected using DharmaFECT Duo reagent
(Dharmacon, T-2020-01) according to the manufacturer’s instructions with luci-
ferase reporter vector and miR-128 mimic (Dharmacon, C-310957-01-0005). Cells
were harvested and assayed for luciferase activity using Dual-GloTM kit (Promega,
E2920) 48 h after transfection as previously described60. Cell lysates were assayed in
a luminometer normalizing ﬁreﬂy to renilla luciferase activity. Data were expressed
as percent inhibition relative to control miRNA mimic transfected cells.
Quantitative real-time PCR (qPCR). Total RNA was isolated using Trizol reagent
(Invitrogen), followed by DNase treatment and puriﬁcation using RNeasy mini
column kit (Qiagen, 74104). Complementary DNA was synthesized using miScript
PCR Starter Kit (Qiagen, 218193) according to the manufacture’s instruction.
qPCR was performed on a CFX96 Real-Time PCR system (Bio-Rad) using the
miScript PCR Starter Kit. The fold changes of each target mRNA expression
relative to GAPDH under experimental and control conditions were calculated
based on the threshold cycle (CT) as r = 2−Δ(ΔCT), where ΔCT = CT(target)−CT
(GAPDH) and Δ(ΔCT) =ΔCT(experimental) − ΔCT(control). The primers for
qPCR are listed in Supplementary Table 1.
Chromatin immunoprecipitation-qPCR (ChIP-qPCR) assay. ChIP assay was
performed as described previously61. Heart tissue was cut into small pieces and
crosslinked with PBS with 1% formaldehyde (Thermo Fisher Scientiﬁc, 28906) at
room temperature for 10 min. Fixation was terminated by addition of 0.125M
(ﬁnal concentration) glycine (Sigma-Aldrich, 50046) at room temperature for 5
min. Chromatin was isolated by addition of lysis buffer, followed by disruption
with a Dounce homogenizer. Lysates were sonicated and sheared into a size range
of ~200–500 bp.
An aliquot of chromatin (30 μg) was precleared with Dynabeads Protein G (Life
Technologies, 10009D) at 4 oC for 1h. The precleared chromatin was
immunoprecipitated using antibodies as follows: SUZ12 (D39F6) (Cell Signaling
Technology, 3737, 1:100), EZH2 (D2C9) (Cell Signaling Technology, 5246, 1:100)
and H3K27me3 (C36B11) (Cell Signaling Technology, 9733, 1:50). Chromatin were
decrosslinked by incubation with proteinase K at 65 °C for overnight, and ChIPed
DNA was puriﬁed by MinElute kit (Qiagen, 28004). Genomic DNA (Input) was
prepared from an aliquot of precleared chromatin by decrosslinking and
puriﬁcation. The resulting DNA was quantiﬁed on a Qubit spectrophotometer.
Western blot analysis. Cells were lysed with ice-cold cell lysis buffer plus protease
inhibitor (Sigma-Aldrich, P8340). Protein samples (40 µg) were mixed and resolved
in 4 × SDS/PAGE sample buffer and boiled for 15 min before loading onto 10%
polyacrylamide gels (Bio-Rad). The electrophoresed proteins were transferred from
the gel to nitrocellulose membranes (Bio-Rad). Equal loading and transfer of
proteins was conﬁrmed by quantitative Ponceau red staining. Membranes were
incubated for 60 min with 5% dry milk and Tris-buffered saline to block non-
speciﬁc binding sites. Membranes were immunoblotted overnight at 4 °C with
antibodies against Cyclin E (M-20) (Santa Cruz, SC-481, 1:500), SUZ12 (D39F6)
(Cell Signaling Technology, 3737, 1:1000), CDK2 (72B2) (Cell Signaling Tech-
nology, 2546, 1:1000), p27 (D69C12) (Cell Signaling Technology, 3686, 1:1000),
PPARγ (81B8) (Cell Signaling Technology, 2443, 1:1000), and GAPDH
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Fig. 10 Loss of miR-128 activates endogenous cardiac regeneration. A
schematic diagram proposing that loss of miR-128 activates cardiac
regeneration by promoting cardiomyocyte proliferation, while the necrotic
tissue of wild-type heart is replaced by myoﬁbroblasts with ﬁbrous scars in
response to MI
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03019-z
14 NATURE COMMUNICATIONS |  (2018) 9:700 |DOI: 10.1038/s41467-018-03019-z |www.nature.com/naturecommunications
(Sigma-Aldrich, G9545, 1:5000) on a rocking platform. After washing three times
for 5-min with Tris-buffered saline, the membranes were incubated for 60 min with
HRP-conjugated secondary antibody, washed three times with Tris-buffered saline,
and developed with the ECL plus kit (Thermo Scientiﬁc). Uncropped immuno-
blotting images are presented in Supplementary Fig. 11.
Neonatal mouse apex resection. Apex resection (AR) was performed on neonatal
mice on postnatal day 1 (P1) as described62. All the neonatal mice were anesthe-
tized by hypothermia (on ice for 3–5 min) placing gauze below the pups. Steady
pressure on the abdomen was applied to exteriorize the heart when the heart was
exposed through a left thoracotomy incision. Then, the ventricular apex was
resected using several incisions until the anatomical landmark of the chamber was
exposed. The hearts were harvested at 6 h, 24 h, 3 days, 7 days, 14 days, and 21 days
post AR. Sham-operated mouse groups (control) underwent chest opening without
AR.
Myocardial infarction (MI). An MI model was developed in female mice, as
previously described61. Brieﬂy, mice (8–10 weeks old) were anesthetized by
spontaneous inhalation and maintained under general anesthesia with 1–2% iso-
ﬂurane. Animals were mechanically ventilated using a rodent ventilator (Harvard
Apparatus) connected to an endotracheal tube. The heart was exposed by a left side
limited thoracotomy and the LAD was ligated with a 6-0 polyester suture 1 mm
from the apex of the normally positioned left auricle.
Echocardiography. Transthoracic echocardiography (Visual Sonics Vevo 2100)
was performed with a 40-MHz probe. Hearts were imaged in 2D long-axis view at
the level of the greatest LV diameter in animals under light general anesthesia. This
view was used to position the M-mode cursor perpendicular to the LV anterior and
posterior walls. LV end-diastolic (LVDd) and end-systolic diameters (LVDs) were
measured from M-mode recordings. LV EF was calculated as: EF% = [(LVDd)3-
(LVDs)3/(LVDd)3 × 100]. LV FS was determined as: FS% = [(LVDd–LVDs)/
LVDd × 100]. All measurements were performed according to the American
Society for Echocardiography leading-edge technique standards, and were averaged
over three consecutive cardiac cycles.
EdU pulse-chase experiment. For EdU (5-ethynyl-2′-deoxyuridine, Life tech-
nology) labeling experiments in vivo, animals were injected intraperitoneally (i.p.)
at 200 µg g−1 body weight. EdU staining was performed with Click-iT EdU Imaging
kit (Thermo Fisher Scientiﬁc, C10337) according to the manufacturer’s
instructions.
Systemic delivery of siRNA in vivo. SiRNA (Dharmacon) against Suz12 (si-
Suz12, L-040180-00-0020) and siRNA control (si-Ctrl, D-001810-01-05) were
formulated with MaxSuppressor™ In Vivo RNA-LANCEr II (Bioo Scientiﬁc,
3410-01) according to the manufacturer’s instructions. The mice were injected i.p.
at 2 µg g−1 body weight with si-Suz12 or si-Ctrl at P1, P3, P5, and hearts were
harvested at P7.
Analysis of left ventricular (LV) ﬁbrotic area. Masson’s trichrome staining was
performed to quantify ﬁbrosis area in the left ventricle post injury. An Olympus
BX41 microscope equipped with CCD (Magna-Fire TM) camera captured LV area
images on each slide. LV ﬁbrosis area and total LV area of each image were
measured using the Image J and ﬁbrosis area was reported as a percentage of the
total LV area.
Immunohistochemistry assay. After deparafﬁnization and microwaving antigen
retrieval in citric acid buffer, heart sections were incubated for 1 h at 37 °C or
overnight at 4 °C with the following antibodies: Anti-cTnT antibody (13-11)
(Thermo Fisher Scientiﬁc, MS-295-P1, 1:100) was used to identify CM. Anti-Ki67
(Abcam, ab15580, 1:200), anti-EdU (Life technology, C10637, 1:500), anti-
phosphorylated-histone 3 (Ser10) (pH3, Millipore, 06-570, 1:100), and Aurora B
(35C1) (Sigma-Aldrich, A2606, 1:100) antibodies were used to analyze cell cycle
activity, DNA synthesis, karyokinesis, and cytokinesis respectively. After triple
washing in PBS, slides were incubated for 45 min at 37 °C with ﬂuorescence
conjugated second antibodies (Jackson Immuno Research). For WGA staining,
slides were incubated for 30 min at 37 °C with primary antibody conjugated to
Alexa Fluo 488 (Thermo Fisher Scientiﬁc, W11261, 1:500) in PBS. To quantify
apoptotic CMs, additional mouse hearts were subjected to TUNEL (Promega) and
cTnT (Thermo Fisher Scientiﬁc, MS-295-P1, 1:100) staining according to the
manufacturer’s instructions. To quantify CM proliferation, cells were stained with
Ki67 and pH3. DAPI was used for nuclear counterstaining. Four ﬁelds of each
section were examined for quantiﬁcation. Fluorescent imaging was performed with
an Olympus BX41 microscope equipped with an epiﬂuorescence attachment.
Statistical analysis. Results were statistically analyzed with the use of the StatView
5.0 software package (Abacus Concepts Inc., Berkeley, CA). All values are
expressed as means ± SEM. Student’s t-test was applied appropriately for
comparison between two treatment groups. One-way ANOVA (using the post-hoc
Bonferroni/Dunn test) was performed for comparisons of multiple groups in each
of the speciﬁc experimental designs presented in the ﬁgures.
Data availability. All of the raw sequencing data from this study have been
submitted to the NCBI GEO (Accession code: GSE107684).
All other supporting data from this study are available from the article and
Supplementary Information ﬁles, or from the corresponding author upon
reasonable request.
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